Eisai has entered into an exclusive license agreement with Huya Bioscience International, a San Diego, California-based biopharmaceutical company, to develop and market the oral histone deacetylase (HDAC) inhibitor HBI-8000 in Japan, South Korea, Thailand, Malaysia, Indonesia, Philippines, Vietnam and Singapore.

HBI-8000 is an oral HDAC inhibitor approved in China for use in the treatment of peripheral T-cell lymphoma (PTCL). HBI-8000 is at the clinical stage of testing in Japan as a treatment for PTCL, a type of non-Hodgkin’s lymphoma, under orphan drug designation from the regulatory authority in Japan. Meanwhile, a Phase I clinical study of the agent in solid tumors has been completed in the United States.

Under the agreement, Eisai has exclusive rights to develop and market HBI-8000 in the licensed territories. However, for PTCL and adult T-cell leukemia-lymphoma, Huya will complete development of the agent for these indications, and Eisai will be responsible for commercialization. According to the agreement, Eisai will pay Huya upfront, development, and commercial milestone payments as well as royalties over the term of the license, respectively.

Source: Eisai